Boltz, a public benefit corporation spun out of MIT CSAIL, launched with $28 million in seed funding to make high‑accuracy open AI models for molecular structure prediction and therapeutic design broadly available. Founders from Regina Barzilay’s lab said Boltz aims to provide open, widely used tools that let scientists go from hypothesis to human‑ready molecule on their desktop. The company unveiled a preview of Boltz Lab and model agents for small‑molecule and protein design. Investors including a16z, Amplify, and Zetta backed the seed, framing Boltz as a platform play to democratize computational drug discovery and accelerate academic and startup pipelines.